Targeting cancer glutamine dependency with a first-in-class inhibitor of the mitochondrial glutamine transporter SLC1A5_var
9.0
来源：
Nature
关键字：
siRNA
发布时间：
2025-11-03 23:56
摘要：
iMQT_020 is a pioneering allosteric inhibitor targeting the mitochondrial glutamine transporter SLC1A5_var, crucial for cancer cell metabolism. This compound disrupts glutaminolysis, leading to reduced tumor growth and enhanced immune responses, particularly in pancreatic cancer. In preclinical models, iMQT_020 demonstrated significant efficacy, suggesting its potential as a novel therapeutic strategy in oncology, especially when combined with immune checkpoint inhibitors.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
1.0分+1.0分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
iMQT_020 is the first reported allosteric inhibitor of SLC1A5_var.
The compound effectively inhibits glutaminolysis and reduces cancer cell viability.
In vivo studies show significant tumor growth inhibition in multiple cancer models.
真实性检查
否
AI评分总结
iMQT_020 is a pioneering allosteric inhibitor targeting the mitochondrial glutamine transporter SLC1A5_var, crucial for cancer cell metabolism. This compound disrupts glutaminolysis, leading to reduced tumor growth and enhanced immune responses, particularly in pancreatic cancer. In preclinical models, iMQT_020 demonstrated significant efficacy, suggesting its potential as a novel therapeutic strategy in oncology, especially when combined with immune checkpoint inhibitors.